Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer
A Phase II Study of Enzomenib in Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well enzomenib works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow or spread despite androgen deprivation therapy (castration-resistant). The growth and survival of prostate tumor cells often depends on testosterone. Androgen deprivation therapy blocks the use of testosterone by the tumor cells. Although most tumors respond to androgen deprivation therapy at first, nearly all eventually progress to a castration-resistant state. Enzomenib, a menin inhibitor, targets and blocks menin, a protein that plays a role in the survival and growth of tumor cells.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
PRIMARY OBJECTIVE:
I. To assess the efficacy of DSP-5336 (enzomenib) as measured by fluorodeoxyglucose (FDG)-positron emission tomography (PET) metabolic response rate, in patients with advanced treatment-refractory prostate cancer.
SECONDARY OBJECTIVES:
I. To determine the safety and tolerability of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.
II. To determine the activity of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.
III To assess the pharmacodynamics of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.
IV. To assess the pharmacokinetics of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.
EXPLORATORY OBJECTIVES:
I. To identify molecular subpopulations associated with response. II. To evaluate circulating tumor deoxyribonucleic acid (DNA) (ctDNA) as a predictor for response.
III. To evaluate differential metabolic responses between prostate-specific membrane antigen (PSMA)-positive and PSMA-negative lesions.
OUTLINE:
Patients continue to receive usual androgen deprivation therapy per standard of care. Patients receive enzomenib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, FDG PET/computed tomography (CT), PSMA PET/CT, CT, bone scan and tissue biopsy throughout the study.
After completion of study treatment, patients are followed up at 30 days then every 3 months for up to 12 months.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
At the time of informed consent, be ≥ 18 years of age. Because no dosing or adverse event data are currently available on the use of DSP-5336 (enzomenib) in patients < 18 years of age, and because prostate cancer is an adult malignancy, pediatric patients are not part of the target disease population, therefore children are excluded from this study
-
Histologically confirmed prostate adenocarcinoma
-
Metastatic disease documented by conventional imaging, including cross-sectional imaging (CT or magnetic resonance imaging [MRI]) and bone scan. Advanced imaging, including PSMA PET/CT or FDG PET/CT, may be used as supportive documentation but is not sufficient as the sole evidence of metastatic disease for eligibility
-
Patients with treated, stable brain metastases are eligible if neurologically stable for ≥ 4 weeks and not requiring corticosteroids for central nervous system (CNS) disease for at least 7 days prior to registration. Routine screening for asymptomatic CNS metastases is not required
-
Participants with documented progressive metastatic castration-resistant prostate cancer (mCRPC), as assessed by the treating physician based on at least 1 of the following criteria:
- Prostate specific antigen (PSA) progression may be used for study eligibility, either alone or with radiographic progression. PSA progression is defined as a rise in PSA that is both ≥ 25% and ≥ 2.0 ng/mL above the lowest PSA value since the start of the most recent systemic therapy, or above the pre-treatment baseline PSA if there was no PSA decline. The rise must be confirmed by a second PSA value obtained at least 3 weeks/21 days later. The reference PSA must be ≥ 1.0 ng/mL. Radiographic disease progression in soft tissue based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
- Radiographic disease progression in bone, defined as appearance of 2 or more new bone lesions on bone scan
-
Participants must have received prior systemic therapy for advanced or metastatic prostate cancer, including both of the following:
- At least one androgen receptor pathway inhibitor, such as abiraterone, enzalutamide, apalutamide, or darolutamide. Androgen receptor pathway inhibitor (ARPI) exposure in the metastatic castration-sensitive, non-metastatic castration-resistant, or metastatic castration-resistant setting may satisfy this requirement and
- At least one prior taxane chemotherapy regimen, such as docetaxel or cabazitaxel, and/or PSMA-targeted radioligand therapy. At least one therapy satisfying this second requirement must have been administered in the metastatic castration-resistant setting
-
Prior poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy, immunotherapy, radium-223, or other standard therapies are permitted but are not required to satisfy eligibility
-
Therapy administered solely in the localized, neoadjuvant, adjuvant, or locally advanced setting does not count toward the required prior therapy history. Docetaxel administered solely in the metastatic castration-sensitive setting does not satisfy the required mCRPC therapy criterion
-
Prior orchiectomy or medical castration, with castrate levels of serum testosterone defined as testosterone ≤ 50 ng/dL documented prior to initiation of study treatment. Participants receiving medical castration with a gonadotrophin releasing hormone (GnRH) agonist or antagonist must continue androgen deprivation therapy throughout the treatment phase
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)
-
Absolute neutrophil count ≥ 1,000/mcL
-
Platelets ≥ 75,000/mcL
-
Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN), except in patients with Gilbert syndrome, who may enroll if total bilirubin is ≤ 3 x institutional ULN and direct bilirubin is ≤ 1.5 x institutional ULN
-
Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotranferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN
-
Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m^2
-
Participants must be willing to undergo baseline and on-treatment tumor biopsies and must have a lesion considered safely accessible for biopsy by the procedural team. Biopsies may be obtained from soft tissue or bone lesions, although soft tissue biopsy is preferred when feasible
-
Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
-
Patients must have disease evaluable for the primary FDG PET metabolic response endpoint, defined as at least one FDG-avid lesion evaluable on baseline FDG PET/CT. The baseline FDG PET/CT must be performed during screening, and the presence of at least one FDG-avid, evaluable lesion must be confirmed prior to registration. RECIST 1.1 measurable disease is not required for eligibility. Patients with RECIST 1.1 measurable disease will be evaluable for RECIST-based secondary response assessments
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better. Participants must have Fridericia's formula-corrected QT interval (QTcF) ≤ 480 msec based on screening electrocardiogram
-
The effects of DSP-5336 (enzomenib) on the developing human fetus are unknown. For this reason and because menin inhibitors agents are known to be teratogenic, men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of DSP-5336 (enzomenib) administration. Participants should not donate sperm for the duration of study participation, and 6 months after completion of the last dose of study drug
Exclusion Criteria:
- Prior treatment with a menin inhibitor (any investigational compound targeting the menin-MLL complex)
- Untreated, symptomatic, active, or progressive CNS metastases
- Inability or unwillingness to undergo FDG and PSMA PET/CT imaging, including inability to lie flat for > 30 minutes. Patients with uncontrolled diabetes mellitus are not eligible if fasting blood glucose cannot be controlled to ≤ 200 mg/dL, or to the institutional threshold required for interpretable FDG PET/CT imaging, despite appropriate medical management
- Known hypersensitivity to DSP-5336 (enzomenib) or any of its excipients
- Patients who have received systemic anticancer therapy, including oral anticancer therapy, chemotherapy, radioligand therapy, immunotherapy, targeted therapy, investigational anticancer agents, or other investigational agents, within 5 half-lives or 14 days, whichever is shorter, prior to initiation of study treatment. Longer washout may be required when clinically appropriate based on unresolved toxicity or prolonged expected pharmacodynamic effect. Patients who have received external beam radiation therapy within 2 weeks prior to initiation of study treatment are not eligible. Routine concomitant medications are permitted unless otherwise prohibited by the protocol. Ongoing androgen deprivation therapy with a GnRH agonist or antagonist is permitted
- Concomitant use of medications known to cause QT prolongation that cannot be safely discontinued or substituted prior to initiation of study treatment
- Patients with uncontrolled intercurrent illness or any other significant condition(s), including active infection requiring intravenous systemic therapy, that would make participation in this protocol unreasonably hazardous
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Treatment (androgen deprivation therapy, enzomenib)
Patients continue to receive usual androgen deprivation therapy per standard of care. Patients receive enzomenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, FDG PET/CT, PSMA PET/CT, CT, bone scan and tissue biopsy throughout the study. |
Undergo blood sample collection
他の名前:
Undergo bone scan
他の名前:
Undergo tissue biopsy
他の名前:
Given FDG
他の名前:
Undergo FDG PET/CT
他の名前:
Given usual androgen deprivation therapy
他の名前:
Undergo CT, FDG PET/CT, and PSMA PET/CT
他の名前:
Given PO
他の名前:
Undergo PSMA PET/CT
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Fluorodeoxyglucose (FDG) positron emission tomography metabolic response rate
時間枠:Up to 12 months
|
Will be defined as the proportion of patients achieving a ≥ 30% reduction from baseline in total FDG uptake (standardized uptake value [SUVtotal]) across all FDG-avid lesions. The response rate will be estimated along with its exact 95% confidence interval (CI). |
Up to 12 months
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of adverse events
時間枠:Up to 30 days after last dose of study treatment
|
Will be graded according to current Cancer Therapy Evaluation Program-required Common Terminology Criteria for Adverse Events version. Will be summarized by type, grade, seriousness, attribution, and relationship to study treatment. |
Up to 30 days after last dose of study treatment
|
|
Overall response rate
時間枠:Up to 12 months
|
Will be evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 and Prostate Cancer Working Group 3 (PCWG3). Will be reported with exact 95% CI where applicable. Will be summarized using Kaplan-Meier methods when appropriate. |
Up to 12 months
|
|
Radiographic progression-free survival (PFS)
時間枠:Up to 12 months
|
Will be summarized using Kaplan-Meier methods when appropriate. |
Up to 12 months
|
|
Prostate specific antigen (PSA)-PFS
時間枠:Up to 12 months
|
Will be summarized using Kaplan-Meier methods when appropriate. |
Up to 12 months
|
|
Duration of response (DOR)
時間枠:From first documented response to radiographic or clinical progression, or death, assessed up to 12 months
|
Kaplan-Meier estimates of median DOR and 95% CIs will be provided. |
From first documented response to radiographic or clinical progression, or death, assessed up to 12 months
|
|
Time to PSA progression
時間枠:From treatment initiation to confirmed PSA progression, will be assessed up to 12 months
|
Progression will be assessed using PCWG3. Will be summarized using Kaplan-Meier methods. |
From treatment initiation to confirmed PSA progression, will be assessed up to 12 months
|
|
Overall survival (OS)
時間枠:From treatment initiation to death from any cause, assessed up to 12 months
|
Will be summarized using Kaplan-Meier estimates, including median OS and 95% CIs. |
From treatment initiation to death from any cause, assessed up to 12 months
|
|
Tumor response signatures
時間枠:Up to 12 months
|
Bulk ribonucleic sequencing will be evaluated for transcriptome changes. Will be summarized using Kaplan-Meier methods when appropriate. |
Up to 12 months
|
|
DSP-5336 (enzomenib) pharmacokinetics (PK)
時間枠:Up to 12 months
|
PK parameters will be summarized descriptively, and exploratory exposure-safety and exposure-response relationships may be evaluated. |
Up to 12 months
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Tumor signatures
時間枠:Up to 12 months
|
Mutations identified by whole exome sequencing (WES) will focus on the PI3K/AKT/mTOR pathway and common alterations associated with prostate cancer, lineage plasticity, and therapeutic resistance. Paired baseline and on-treatment tumor samples will be used to assess pharmacodynamic changes in transcriptional programs and AKT pathway signaling. Baseline tumor WES with matched germline deoxyribonucleic acid (DNA) will be used to characterize genomic alterations in the enrolled population. |
Up to 12 months
|
|
Change in variant allele frequencies of tumor mutations in circulating tumor DNA (ctDNA)
時間枠:At cycle 3 (cycle length = 28 days)
|
Will be compared to pretreatment. Serial ctDNA dynamics will be explored for association with metabolic response, radiographic response/progression, and clinical outcomes. Given the sample size, correlative analyses will be hypothesis-generating. |
At cycle 3 (cycle length = 28 days)
|
|
Change in FDG uptake (SUVtotal) in prostate-specific membrane antigen (PSMA)-positive and PSMA-negative lesions
時間枠:Up to 12 months
|
Exploratory imaging analyses will evaluate metabolic response globally and, when feasible, by lesion phenotype, including PSMA-positive and PSMA-negative lesions. Lesion-level analyses will be descriptive and exploratory, with attention to within-patient heterogeneity. |
Up to 12 months
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Adel Mandl、JHU Sidney Kimmel Comprehensive Cancer Center LAO
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 性器腫瘍、男性
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 生殖器疾患、男性
- 前立腺疾患
- 男性の泌尿生殖器疾患
- 前立腺腫瘍
- 薬物の生理学的影響
- ホルモン、ホルモン代替品、ホルモン拮抗薬
- ホルモン拮抗薬
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 細胞学的技術
- 細胞診断
- 薬理学的行動
- 化学作用と用途
- 炭水化物
- ヒドロラーゼ
- 酵素
- 酵素と補酵素
- 診断技術、外科的
- デオキシグルコース
- デオキシ糖
- ペプチドヒドロラーゼ
- メタロプロテアーゼ
- カルボキシペプチダーゼ
- エキソペプチダーゼ
- メタロエキソペプチダーゼ
- フルオロデオキシグルコース F18
- アンドロゲン拮抗薬
- 生検
- 標本処理
- グルタミン酸カルボキシペプチダーゼII
その他の研究ID番号
その他の研究ID番号
- NCI-2026-07869
- UM1CA186691 (米国 NIH グラント/契約)
- NCI-2026-07869 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- 10790 (その他の識別子:JHU Sidney Kimmel Comprehensive Cancer Center LAO)
- 10790 (その他の識別子:CTEP)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。